INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces its financial calendar for 2012 as well as its participations to upcoming investor conferences

Transparency directive : regulatory news

21/12/2011 07:30

Press release

INNATE PHARMA ANNOUNCES ITS FINANCIAL CALENDAR FOR 2012 AS WELL AS ITS
           PARTICIPATION TO UPCOMING INVESTOR CONFERENCES

Marseilles, France, December 21, 2011

Innate Pharma SA (Euronext Paris: FR0010331421 - IPH), the innate immunity
company developing first-in-class drugs for cancer and inflammatory diseases,
announces today its tentative financial calendar for 2012, which is set as
follows:

February 7, 2012:  Publication of revenue for 4Q2011 and for the 2011 fiscal
                   year, with management comments.
March 6, 2012:     Publication of 2011 financial statements, with management
                   comments. The 2011 Reference Document and Financial Report
                   (included in the Reference Document) will be released during
                   the second quarter of 2012.
May 10, 2012:      Publication of revenue for 1Q2012, with management comments.
June 28, 2012:     Annual shareholders meeting in Marseilles.
September 6, 2012: Publication of mid-year financial statements as of June 30,
                   2012, with management comments.
November 14, 2012: Publication of revenue for 3Q2012, with management comments.

During the first quarter of 2012, Innate Pharma will participate in the
following investor conferences:

Oddo Midcap Event - Palais des congrès, Lyon, on January 5 & 6, 2012;

SFAF Biotech Day - SFAF, Paris, on January 20, 2012;

European Life Science CEO Forum - Hilton Airport Hotel, Zurich, on March 6,
2012.
During this event, Hervé Brailly, CEO of Innate Pharma, will participate in a
panel discussion on "French Public Markets - Breakthrough Technologies"

Innate Pharma is committed to meet on a regular basis with the financial
community. Investors can also find updated information on the company's website
(www.innatepharma.com) and contact the investor relations team by writing to
investors@innatepharma.com.

All corporate information on the Company such as its financial statements or its
corporate presentations is available on the Company's website, in the Investors'
section (www.innatepharma.com/investors-room).

About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. The Company's innovative approach has been validated by licence
agreements with two major pharmaceutical companies, Novo Nordisk A/S and
Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma
is based in Marseilles, France, and had 81 employees as at September 30, 2011.

Learn more about Innate Pharma at www.innate-pharma.com

Practical Information about Innate Pharma shares:
ISIN code         Ticker code
FR0010331421      IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:
Innate Pharma                  French enquiries
                               ATCG Press
Laure-Hélène Mercier           Marielle Bricman
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87    Mob.: +33 (0)6 26 94 18 53
investors@innate-pharma.com    mb@atcg-partners.com

International enquiries
M :Communications
Peter Laing, Amber Bielecka,
Hollie Vile
Phone: +44 (0)20 7920 2330
innatepharma@mcomgroup.com

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces its financial calendar for 2012 as well as its participations to upcoming investor conferences

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories